U.S. Markets closed

Conatus Pharmaceuticals Inc. (CNAT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5560+0.0010 (+0.18%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

    Conatus Pharmaceuticals Inc. (CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and recommendations, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. (“Histogen”) and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020. “We are very pleased that these highly influential proxy advisor firms have recommended that our stockholders vote in favor of the proposals to merger with Histogen and the required reverse stock split,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus.

  • GlobeNewswire

    Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

    Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. In a spinal disc study, HST 004 reversed inflammation and protease activity and stimulated aggrecan secretion in the thrombin-induced rabbit ex vivo model.

  • GlobeNewswire

    Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

    Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men. Under this IND, Histogen intends to initiate a Phase 1b/2a clinical trial of HST 001, a Hair Stimulating Complex (HSC), in the second quarter of 2020. This clinical trial is designed to assess the safety, tolerability and efficacy of HST 001, as well as determine optimal dosing in male pattern hair loss.